Sensitivity to CCK-4 in Women with and without Premenstrual Dysphoric Disorder (PMDD) During Their Follicular and Luteal Phases

Mellédo, Jean-Michel Le; Merani, S; Koszycki, Diana; Bellavance, François; Palmour, Roberta M.; Gutkowska, Jolanta; Steinberg, Susanne; Bichet, Daniel G.; Bradwejn, Jacques

doi:10.1016/s0893-133x(98)00057-8

Cited by 41 publications

(25 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This supports the findings of Le Mellédo et al 1999, who described a stable baseline CCK-LI independent of menstrual phase [11]. Frick et al had earlier found a variation in plasma with higher concentrations of CCK in LP than in FP in women in 1990 [5], however, this study was small, made before more specific CCK analysis methods had been discovered, and may explain our divergent findings.…”

Section: Discussionsupporting

confidence: 89%

“…Frick et al had earlier found a variation in plasma with higher concentrations of CCK in LP than in FP in women in 1990 [5], however, this study was small, made before more specific CCK analysis methods had been discovered, and may explain our divergent findings. In any case, neither we nor Le Mellédo [11] could repeat the findings of Frick.…”

Section: Discussioncontrasting

confidence: 56%

“…In 1990, Frick et al found a variation with higher concentrations of CCK in plasma in the luteal phase compared to the follicular phase [5]. In contrast, Le Mellédo et al 1999 could not confirm this variation and found no significant differences between the basal CCK-like immunoreactivity (CCK-LI) in the luteal and follicular phases [11].…”

Section: Introductionmentioning

confidence: 98%

“…Women with premenstrual dysphoric disorder have shown greater anxiety and panic response when injected with CCK-4 compared to controls [11]. The question arises if there is a connection between CCK and premenstrual symptoms in humans.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cholecystokinin in plasma and cerebrospinal fluid—A study in healthy young women

et al. 2010

View full text Add to dashboard Cite

ABSTRACT:Cholecystokinin (CCK) is widely distributed in the brain and is known to affect behavioral and physiological functions including anxiety and pain. The expression of CCK has been shown to be regulated by estrogen and to vary during the estrous cycle in rat brain. In the present study CCK was determined in plasma from 25 healthy women (age 25.0 ± 3.5) during the menstrual cycle, in the late luteal phase and in the follicular phase. In the follicular phase, a lumbar puncture was performed at the same time that a plasma sample was taken in 15 subjects. The participants had fasted and were nicotine-free for at least 8 h preceding the sampling.We compared CCK-like immunoreactivity (CCK-LI) in plasma from 25 subjects in the late luteal phase (LLP) and the follicular phase (FP) and found that there was no difference during the menstrual cycle (n=25, R²=89,60%, p= n.s.). In the follicular phase no significant difference was found between CCK-LI in plasma and in cerebrospinal fluid (CSF) collected at the same time (n=15, R²=55,32%, p=n.s.).

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 56%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cholecystokinin in plasma and cerebrospinal fluid—A study in healthy young women

et al. 2010

View full text Add to dashboard Cite

show abstract

“…With respect to syndrome specificity, CCK-4 and pentagastrin provoke panic attacks more frequently in PD patients than in NCs [Bradwejn et al, 1991b;van Megan et al, 1994]. However, sensitivity to CCK 2 receptor agonists is not limited to PD as patients with generalized anxiety disorder (GAD) [Brawman-Minzter et al, 1997], social phobia (SP) [McCann et al, 1997;van Vliet et al, 1997], obsessive-compulsive disorder (OCD) [de Leeuw et al, 1996], post-traumatic stress disorder (PTSD) [Kellner et al, 2000], and premenstrual dysphoric disorder (PMDD) [Le Melledo et al, 1999] also exhibit an augmented behavioral response compared to NCs. Nevertheless, the threshold of panic vulnerability seems to be lower in PD relative to these other disorders.…”

Section: Introductionmentioning

confidence: 99%

Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder

2004

View full text Add to dashboard Cite

Panicogenic sensitivity to CCK-tetrapeptide (CCK-4) is enhanced in panic disorder patients relative to normal controls (NC). We sought to determine whether CCK-4 sensitivity is augmented in patients with social phobia (SP) (n = 12) and obsessive-compulsive disorder (OCD) (n = 8) versus NC (n = 12). We also determined whether CCK-4 could elicit syndrome-specific symptoms in SP and OCD patients. The study employed a single-blind, placebo-controlled, within-subject design. Behavioral, cardiovascular and hormonal responses to a submaximal dose (20 microg) of CCK-4 were evaluated. Panic frequency after the placebo and CCK-4 challenge varied as a function of diagnosis. Differences in panic frequency between groups and between challenge agents within each group did not, however, reach statistical significance. Further, the number and intensity of panic symptoms, intensity of subjective anxiety, autonomic reactivity and hormonal release after CCK-4 administration did not distinguish the groups. Core symptoms of SP and OCD were unaffected by CCK-4. These data failed to detect significant differences between groups on behavioral, cardiovascular and hormonal response to CCK-4. The lack of effect of CCK-4 on SP and OCD symptoms suggests that this peptide does not play a salient role in the pathophysiology of these disorders.

show abstract

Pharmacological Challenge Agents in Anxiety

et al. 2002

View full text Add to dashboard Cite

Sensitivity to CCK-4 in Women with and without Premenstrual Dysphoric Disorder (PMDD) During Their Follicular and Luteal Phases

Cited by 41 publications

References 51 publications

Cholecystokinin in plasma and cerebrospinal fluid—A study in healthy young women

Cholecystokinin in plasma and cerebrospinal fluid—A study in healthy young women

Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder

Pharmacological Challenge Agents in Anxiety

Contact Info

Product

Resources

About